Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variations in GLP-1R: Impact on diabetes and obesity therapeutics.

European journal of pharmacology - 15 Apr 2026

Al-Zaid Bashaier, Abubaker Jehad, Mohammad Anwar, Abufarha Mohamed, Al-Mulla Fahd, Al-Sabah Suleiman

Abstract excerpt

The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) that is essential for glucose homeostasis, energy balance and appetite. GLP-1R is a key therapeutic target for the treatment of type 2 diabetes and obesity, owing to its central role in insulin secretion, glucagon suppression, and body weight regulation. Increasing evidence suggests that genetic polymorphisms in GLP-1R...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes Mellitus, Type 2
Share to Diabetes Treatment and Management

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Variation

Share to Glucagon-Like Peptide-1 Receptor

Share to Obesity

Share to Pancreatic function and diabetes

Share to Polymorphism, Single Nucleotide

Share to Regulation of Appetite and Obesity

Source

Identifiers

PMID: 41905447
DOI: 10.1016/j.ejphar.2026.178805

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variations in GLP-1R: Impact on diabetes and obesity therapeutics.PMID 41905447Read ↗

Human GLP1R variants affecting GLP1R cell surface expression contribute to impaired glucose control and increased adipositySemantic proximity Read ↗

GLP1R (glucagon-like-peptide-1 incretin receptor), diabetes and obesity phenotypes: An in silico approach revealed new pathogenic variants.Semantic proximity Read ↗

Biased agonism and polymorphic variation at the GLP-1 receptor: Implications for the development of personalised therapeuticsSemantic proximity Read ↗

Pharmacogenomics of GLP-1 Receptor Agonists: A genome wide analysis of observational data and large randomized controlled trialsSemantic proximity Read ↗

Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery.Semantic proximity Read ↗

Global glucagon-like peptide-2 receptor activation linked to increased obesity risk in the UK Biobank.Semantic proximity Read ↗

GLP1R Variants and Polygenic Risk Underlie Heterogeneous Response to GLP-1 Receptor Agonists in Type 2 DiabetesSemantic proximity Read ↗

Pharmacogenomics of GLP-1 Receptor Agonists: Precision Medicine in the Age of Ozempic and MounjaroSemantic proximity Read ↗

Naturally occurring mutations in G protein-coupled receptors associated with obesity and type 2 diabetes mellitus.Semantic proximity Read ↗

Association of GLP1R variants rs2268641 and rs6923761 with obesity and other metabolic parameters in a Polish cohortSemantic proximity Read ↗

Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes.Semantic proximity Read ↗

A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.